A Phase 2/3 Study to Evaluate the Safety and Efficacy of GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Subjects with HIV-1 Infection.midwayadmin2020-05-15T15:13:57+00:00
A Phase 2/3 Study to Evaluate the Safety and Efficacy of GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Subjects with HIV-1 Infection.
GS-US-200-4625 · Trial ·
Major Inclusion/Exclusion Criteria:
- Multiple resistance to HIV therapy
- HIV RNA >500 copies